| 摘要 |
<p>The use of recombinant IFN-beta for the production of a medicament for the treatment of HCV infection by subcutaneous administration to patients of Asian race, which failed to respond to a previous treatment with interferon -alpha, is herein reported. According to a preferred embodiment of the invention, this treatment can be better and further focused to those patients, which after 4 weeks of initial treatment with IFN-beta show HCV RNA clearance.</p> |
